Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms.
10.1016/j.afos.2017.05.002
- Author:
Ravisha WADHWA
1
;
Manoj KUMAR
;
Sushama TALEGAONKAR
;
Divya VOHORA
Author Information
1. Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. divyavohora@hotmail.com
- Publication Type:Review
- Keywords:
Selective serotonin reuptake inhibitors;
Fracture;
Bone mineral density;
Serotonin;
Bone
- MeSH:
Antidepressive Agents;
Bone Density;
Depression;
Humans;
Metabolism;
Prescriptions;
Receptors, Serotonin;
Serotonin Uptake Inhibitors*;
Serotonin*
- From:Osteoporosis and Sarcopenia
2017;3(2):75-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
Selective serotonin reuptake inhibitors (SSRIs) are currently the treatment of choice in depression and constitute major portion of prescription in depressive patients. The role of serotonin receptors in bone is emerging, raising certain questions regarding the effect of blockade of serotonin reuptake in the bone metabolism. Clinical studies have reported an association of SSRI antidepressants which with increase in fracture and decrease in bone mineral density. This review focus on recent evidence that evaluate the association of SSRIs with the risk of fracture and bone mineral density and also the probable mechanisms that might be involved in such effects.
